TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,094,256 | +180.5% | 122,400 | +381.9% | 0.51% | +184.3% |
| Q2 2023 | $390,098 | -85.8% | 25,397 | -79.2% | 0.18% | -92.0% |
| Q1 2023 | $2,740,047 | +6.9% | 121,834 | 0.0% | 2.23% | +46.7% |
| Q4 2022 | $2,562,169 | -6.1% | 121,834 | +10.1% | 1.52% | -2.4% |
| Q3 2022 | $2,728,000 | +8.1% | 110,698 | +6.3% | 1.56% | +2.2% |
| Q2 2022 | $2,524,000 | +201.2% | 104,150 | +220.5% | 1.52% | +185.9% |
| Q1 2022 | $838,000 | -50.1% | 32,501 | -39.9% | 0.53% | -60.1% |
| Q4 2021 | $1,679,000 | +22.1% | 54,103 | -4.6% | 1.34% | +46.9% |
| Q3 2021 | $1,375,000 | +76.1% | 56,694 | +6.0% | 0.91% | +64.3% |
| Q2 2021 | $781,000 | +27.0% | 53,498 | +117.3% | 0.55% | +21.2% |
| Q1 2021 | $615,000 | – | 24,622 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |